### Accepted Manuscript

Synthesis, in vitro antimalarial activities and cytotoxicities of amino-artemisinin-ferrocene derivatives

Christo de Lange, Dina Coertzen, Frans J. Smit, Johannes F. Wentzel, Ho Ning Wong, Lyn-Marie Birkholtz, Richard K. Haynes, David D. N'Da

PII:	S0960-894X(17)31231-3
DOI:	https://doi.org/10.1016/j.bmc1.2017.12.057
Reference:	BMCL 25513
To appear in:	Bioorganic & Medicinal Chemistry Letters
Received Date:	7 October 2017
Revised Date:	20 December 2017
Accepted Date:	23 December 2017



Please cite this article as: de Lange, C., Coertzen, D., Smit, F.J., Wentzel, J.F., Wong, H.N., Birkholtz, L-M., Haynes, R.K., N'Da, D.D., Synthesis, in vitro antimalarial activities and cytotoxicities of amino-artemisinin-ferrocene derivatives, *Bioorganic & Medicinal Chemistry Letters* (2017), doi: https://doi.org/10.1016/j.bmcl.2017.12.057

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

### **Graphical Abstract**

Synthesis, in vitro antimalarial activities and cytotoxicities of amino-artemisinin-ferrocene derivatives	Leave this area blank for abstract info.
Christo de Lange, Dina Coertzen, Frans J. Smit, Johannes Birkholtz, Richard K. Haynes* and David D. N'Da*	s F. Wentzel, Ho Ning Wong, Lyn-Marie
Num (mH)	<i>P. falciparum</i> IC <sub>50</sub> nM NF54: 4.5; K1: 2,7 W2: 3.2 <i>Cytotoxicity</i> IC <sub>50</sub> μM Hek293: 53.0
Fe 6	Antitumor IC <sub>50</sub> μM A375: 19.0



Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com

### Synthesis, in vitro antimalarial activities and cytotoxicities of amino-artemisininferrocene derivatives

Christo de Lange<sup>a</sup>, Dina Coertzen<sup>b</sup>, Frans J. Smit<sup>a</sup>, Johannes F. Wentzel<sup>a</sup>, Ho Ning Wong<sup>a</sup>, Lyn-Marie Birkholtz<sup>b</sup>, Richard K. Haynes<sup>a\*</sup> and David D. N'Da<sup>a\*</sup>

<sup>a</sup>Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa

<sup>b</sup>Department of Biochemistry, Institute for Sustainable Malaria Control, University of Pretoria, Private Bag X20, Hatfield 028, South Africa

#### ARTICLE INFO

- Article history: Received Revised Accepted Available online
- Keywords: Amino-artemisinin Ferrocene Redox Hybrid Malaria

#### ABSTRACT

Novel derivatives bearing a ferrocene attached via a piperazine linker to C-10 of the artemisinin nucleus were prepared from dihydroartemisinin and screened against chloroquine (CQ) sensitive NF54 and CQ resistant K1 and W2 strains of *Plasmodium falciparum (Pf)* parasites. The overall aim is to imprint oxidant (from the artemisinin) and redox (from the ferrocene) activities. In a preliminary assessment, these compounds were shown to possess activities in the low nM range with the most active being compound **6** with IC<sub>50</sub> values of 2.79 nM against *Pf* K1 and 3.2 nM against *Pf* W2. Overall the resistance indices indicate that the compounds have a low potential for cross resistance. Cytotoxicities were determined with Hek293 human embryonic kidney cells and activities against proliferating cells were assessed against A375 human malignant melanoma cells. The selectivity indices of the amino-artemisinin ferrocene derivatives indicate there is overall an appreciably higher selectivity towards the malaria parasite than mammalian cells.

According to the World Health Organization (WHO), there were about 212 million cases of malaria amounting to approximately 429,000 deaths in 2015, of which the majority of deaths were recorded in Africa.<sup>1</sup> The most important parasite, *Plasmodium falciparum* (Pf) has acquired resistance to most drugs, including most recently the clinically-used artemisinins.<sup>2-6</sup> As an example, in some areas of Western Cambodia the ACT comprising dihydroartemisinin (DHA)-piperaquine failed to cure half of all patients treated.<sup>2-3</sup> In general, DHA 1 is either used as such, or is the active metabolite of the other clinically used artemisinins artemether and artesunate due to the metabolism of the C-10 methyl ether or facile hydrolysis of the succinate ester respectively.<sup>4</sup> It appears that DHA is implicated in artemisinin resistance.<sup>5,6</sup> Thus, it is necessary to avoid the formation of this metabolite, and so it is best to consider new derivatives not bearing an oxygen atom attached to C-10. We have shown elsewhere that artemisone, a derivative bearing an amino group at C-10 is not metabolized to DHA.<sup>7</sup> Further, in terms of their in vitro activities, C-10 substituted amino-artemisinins in general appear to be optimal substrates in direct comparison with C-10 O- and C-substituted counterparts.<sup>8</sup> We have shown that artemisinins act as oxidant drugs through the ability of the peroxide group to rapidly oxidize intracellular components such as reduced flavins of flavin disulfide reductases, and thereby perturb redox homeostasis in the malaria parasite.<sup>9,10</sup> The peroxide is reduced irreversibly through accepting electrons from the reduced flavin. Thus, a possible further means to address resistance is to seek additional modes of action by modifying the structure of the artemisinin through attachment of groups that may act as pharmacophores in their own right. The ferrocene pharmacophore acts as a redox centre that undergoes redox cycling. The ferrocene-Fe<sup>2+</sup> may be oxidized by free or labile Fe<sup>3+</sup> to form ferrocenium (ferrocene-Fe<sup>3+</sup>).<sup>11-13</sup> In the last case, the labile Fe<sup>2+</sup> thereby generated is oxidized by oxygen to form superoxide; subsequent reaction with  $Fe^{2+}$  via the Fenton pathway generates hydroxyl radicals. Thus, the increased production of reactive oxygen species (ROS) leads to perturbation of parasite redox homeostasis. Importantly, ferrocinium is reduced to ferrocene by metalloproteins (ferrocytochrome c), NADH and thiols such as glutathione (GSH).<sup>14-17</sup> Given that thiols are capable reductants, ferrocinium very likely is reduced also by reduced flavins (that like thiols rapidly reduce labile Fe<sup>3+</sup>), although evidently this has yet to be demonstrated.<sup>18-20</sup> Thus, by attaching the redox active moiety to the oxidant artemisinin, the overall ability of the ensemble of oxidant and redox centres to enhance oxidative stress is greatly increased; that is, once the peroxide pharmacophore is reduced, the ferrocene is able to continue the cycle of oxidation and reduction thereby maintaining oxidative stress in the parasite. It is noted that artemisinin-ferrocene derivatives have been prepared previously and their antimalarial activities have been assessed essentially in terms of their binding to heme.<sup>21,22</sup> The most noteworthy aspect of these hybrids is the evidently mutual compatibility of the peroxide with the ferrocene ferrous iron, even though free ferrous iron, with its admittedly lower oxidation potential than that of ferrous iron in ferrocene or ferrous iron in heme, are popularly ascribed to 'activating' the peroxide to induce formation of 'toxic' free radicals from the artemisinin peroxide.<sup>23</sup> This toxic radical concept has been thoroughly dissected on the basis of the well-established chemistry of carbon-centred free radicals and is

difficult to reconcile with the behaviour of artemisinins in presence of free or heme-ligated ferrous iron.<sup>24</sup> Be that as it may, as an exploratory venture into probing efficacies of artemisinin-ferrocene hybrids in terms of the oxidant-redox activity concept, we sought here to exploit the unique activities of C-10 amino-artemisinins through attachment of the redox-active ferrocene pharmacophore to the amino group.

DHA **1** in toluene in the presence of catalytic dimethyl sulfoxide was quantitatively converted by oxalyl chloride into the  $10\beta$ -chloride and the latter treated *in situ* with piperazine to provide  $10\alpha$ -(1'-piperazino)-10-deoxo-10-dihydroartemisinin **2** (Scheme 1).<sup>25</sup> That this and the final derivatives possessed the  $10\alpha$ -stereochemistry was confirmed by the coupling constant of *J* 10.2 Hz between H-10 and H-9 in **2**, which is consistent with an *anti*-periplanar (*trans*-diaxial) arrangement of these protons in a chair pyranose ring.<sup>26</sup> This intermediate proved to be sufficiently stable for attachment of the ferrocene moiety. Friedel-Crafts acylation of ferrocene with the corresponding acyl halides gave 1-ferrocenyl-3-chloropropan-1-one (27%), 1-ferrocenyl-5-bromopentan-1-one (79%) and 1-ferrocenyl-6-bromohexan-1-one (83%) according to literature methods.<sup>27</sup> These intermediates were condensed with the piperazine derivative **2** in the presence of DBU to give the derivatives **3-5**. 1-Ferrocenyl-2-chloroethan-1-one and 1-ferrocenyl-4-chlorobutan-1-one were also prepared, but although the final piperazine derivatives were obtained after condensation with **2**, these could not be purified, thus precluding their further examination. For preparation of the ferrocene methyl derivative **6**, the piperazine intermediate **2** was submitted to reductive alkylation products **7-9**, the ferrocenoyl halides were reduced with borane *tert*-butylamine and aluminium chloride to give the ferrocenyl alkyl halides (84-98%).<sup>28</sup> However, alkylation of the piperazine intermediate **2** with these alkyl halides was not straightforward, and microwave radiation had to be used to drive the reactions so as to provide the final derivatives **7-9** in approximately 20% yields.

In vitro antiplasmodial activity was determined against the chloroquine sensitive (CQS) NF54 strain and chloroquine resistant (CQR) K1 and W2 strains of P. falciparum (Pf) using the SYBR Green I based fluorescence assay to measure parasite proliferation.<sup>29</sup> The resistance index (RI) for each drug resistant strain (ratio of the IC<sub>50</sub> values of the resistant to sensitive strains IC<sub>50</sub> K1/ IC<sub>50</sub> NF54 and IC<sub>50</sub>W2/IC<sub>50</sub>NF54) was calculated as an indication of potential cross-resistance formation. The in vitro cytotoxicity assay was performed on human embryonic kidney cells Hek293 and anti-tumour screening was carried out on the human malignant melanoma cell line A375 as described previously.<sup>30</sup> The selectivity indices (SI) indicate the selectivity of the compounds towards *Pf* or cancer cells compared to mammalian cells in vitro. The amino-artemisinin-ferrocene derivatives showed good activity on asexual parasites with IC<sub>50</sub> values in the low nM range (Table 1). The ferrocene derivatives in general tend to be less active than the comparator drugs dihydroartemisinin and artesunate (Table 1). The RI values of all of the amino-artemisinin-ferrocene derivatives were smaller than 1, which indicates a low potential for cross resistance and similar to the indices for the artemisinin reference compounds (Table 1). With the exception of compound 5, most compounds showed good selectivity for Pf parasites, with SI indices >9000. Compound 5, the least active compound towards Pf, was more cytotoxic towards mammalian cells than cancer cells. It is noted that compounds 4, 8 and 9 were relatively poorly soluble in the culture medium, and meaningful data could not be obtained for compound 4. The solubility issues aside, the three most active amino-artemisinin-ferrocene derivatives were 3, 6 and 7. Not unexpectedly, electron withdrawing substituents attached to the ferrocene decrease the ease of oxidation of the  $Fe^{2+}$  centre and electron donating groups have the reverse effect.<sup>31-34</sup> However, even though the atom adjacent to the ferrocene ring comprises different functional groups, namely electron withdrawing carbonyl for compound 3, and electron-donating amino-methylene for compound 6 and methylene for compound 7, activities do not vary significantly, indicating that such effects are insignificant in these screens. Conversion of DHA 1, that has  $IC_{50}$ values of  $4 \pm 1 \mu M$  on the Hek293 cell line and  $1 \pm 0.1 \mu M$  on the A375 cell line, via the amino-artemisinin 2 into the derivatives 3, 6 and 7 results in greatly enhanced selectivities with respect to the malaria parasites (Table 1).<sup>35,36</sup> In terms of overall accessibility and activities, compound 6 is identified as a hit compound.

Thus, in summary, we have demonstrated that the amino-artemisinin ferrocene derivatives retain good antimalarial activities and display good selectivities *in vitro* towards *Pf*. Clearly, in order to evaluate any role played by the ferrocene pharmacophore, it is necessary to conduct *in vivo* assays to establish if there are indeed any differences between the parent amino-artemisinin and the amino-artemisinin-ferrocene conjugates wherein redox cycling of the ferrocene moiety should continue once the peroxide of the artemisinin is reduced *in vivo*. Overall, the work provides a useful incipient structure-activity profile for the preparation of newer compounds that together with **6** will be screened both against artemisinin resistant parasites, and *in vivo* involving a murine model to assess effects of the ferrocene moiety on activities.





**Scheme 1.** Synthesis routes for amino-artemisinin-ferrocene derivatives and yields i. **1** (1 eq.), toluene, dimethyl sulfoxide (0.1 eq.), N<sub>2</sub>, oxalyl chloride (1.1 eq.), room temperature, 2 h; piperazine (5 eq.), dichloromethane, N<sub>2</sub>, room temperature, 16 h, 35%. ii. **2** (1 eq.), acetonitrile, ferrocenoyl halide (X = Cl, Br, see text) (1 eq.), DBU (0.225 eq.), room temperature, 24 h. iii. Ferrocenecarboxaldehyde (1 eq.), **2** (3.1 eq.), THF, N<sub>2</sub>, sodium triacetoxyborohydride (2.5 eq), room temperature, overnight. iv. **2** (1 eq.), acetonitrile, ferrocene alkyl halide (1 eq.), DBU (2 eq.), 0.1 mL DMF, microwave.

	Compd	Antimalarial activity $IC_{50}(\pm SEM)$ nM					Cytotoxicity		Antitumour	
	Compu						IC <sub>50</sub> (µM)		IC <sub>50</sub> (µM)	
		NF54	K1	$RI^{a}$	W2	RI <sup>b</sup>	Hek293	SI <sup>c</sup>	A375	$SI^d$
	CQ	10.0 (3.0)	154.0 (14.0)	15.4	233.0 (49.0)	23.3	nd	nd	nd	nd
	DHA 1	2.5 (0.1)	1.5 (0.3)	0.6	1.7 (0.2)	0.6	$4.0^{\rm e}$	1593	$1.0^{e}$	0.3
	Ars	3.0 (0.2)	4.0 (1.0)	1.3	2.4 (0.4)	0.8	nd	nd	nd	nd
	Arm	1.8 (0.1)	9.0 (2.0)	4.8	7.0 (1.0)	3.8	nd	nd	nd	nd
	2	3.0 (0.3)	2.1 (0.4)	0.7	2.9 (0.6)	0.8	30.0	9780	76.0	0.3
	3	9.0 (4.7)	5.0 (2.6)	0.5	6.5 (3.9)	0.7	192.0	21309	61.0	3.1
	5	24.1 (6.0)	16.8 (1.5)	0.7	19.8 (4.1)	0.8	17.0	703	54.0	0.3
	6	4.5 (0.6)	2.7 (0.7)	0.6	3.2 (1.0)	0.7	53.0	11597	19.0	2.7
	7	7.7 (3.0)	4.6 (1.9)	0.6	5.9 (3.2)	0.7	266.0	34456	111.0	1.6
	8	nd	nd	nd	nd	nd	13.0	nd	8.0	1.6
	9	nd	nd	nd	nd	nd	134.0	nd	8.0	16.7

Table 1. Biological activities of amino-artemisinin-ferrocene derivatives

CQ chloroquine; DHA dihydroartemisinin; Ars artesunate; Arm artemether; nd not determined; Hek293 human embryonic kidney cells, A375 human malignant melanoma cells; <sup>a</sup>Resistance Index =  $IC_{50}$  K1/IC<sub>50</sub> NF54; <sup>b</sup>Resistance Index =  $IC_{50}$  W2/IC<sub>50</sub> NF54; <sup>c</sup>Selectivity Index =  $IC_{50}$  Hek293/ IC<sub>50</sub> NF54; <sup>d</sup>Selectivity Index =  $IC_{50}$  Hek293/ IC<sub>50</sub> A375; <sup>e</sup>historical values

#### Acknowledgments

This work was funded by the South African Medical Research Council (MRC) Flagship Project MALTB-Redox with funds from National Treasury under its Economic Competitiveness and Support Package and South African National Research Foundation Grants to R. K. Haynes (UID 90682 and UID 98934) and to D. D. N'Da (UID 76443). The authors thank Mr. A Joubert for NMR analysis and Dr. JHL Jordaan for MS analysis.

#### References

- 1. World Health Orginization. World Malaria Report 2016 summary.
- http://apps.who.int/iris/bitstream/10665/252038/1/9789241511711-eng.pdf.
- 2. Fairhurst RM, Dondorp AM. Artemisinin-resistant *Plasmodium falciparum* malaria. *Microbiol Spectr.* 2016; 4(3): 10.
- 3. World Health Organization. *Emergency response to artemisinin resistance in the Greater Mekong subregion: regional framework for action*, 2013–2015. http://www.who.int/malaria/publications/atoz/9789241505321/en/.
- Haynes RK. From artemisinin to new artemisinin antimalarials: biosynthesis, extraction, old and new derivatives, stereochemistry and medicinal chemistry requirements. *Curr Top Med Chem.* 2006; 6(5): 509-537.
- 5. Mbengue A, Bhattacharjee S, Pandharkar T, et al. A molecular mechanism of artemisinin resistance in *Plasmodium falciparum* malaria. *Nature*. 2015; 520(7549): 683-687.
- 6. Paloque L, Ramadani AP, Mercereau-Puijalon O, Augereau JM, Benoit-Vical F. *Plasmodium falciparum*: multifaceted resistance to artemisinins. *Malaria J*. 2016; 15(1): 149.
- Haynes RK, Fugmann B, Stetter J, et al. Artemisone—a highly active antimalarial drug of the artemisinin class. *Angew Chem Int Ed.* 2006; 45(13): 2082-2088.
- 8. Wu Y, Wu RWK, Cheu KW, et al. Methylene homologues of artemisone: an unexpected structure–activity relationship and a possible implication for the design of C10-substituted artemisinins. *ChemMedChem.* 2016; 11(13): 1469-1479.
- Haynes RK, Cheu KW, Chan HW, et al. Interactions between artemisinins and other antimalarial drugs in relation to the cofactor model—a unifying proposal for drug action. *ChemMedChem*. 2012; 7(12): 2204-2226.
- 10. Haynes RK, Cheu KW, Tang MMK, et al. Reactions of antimalarial peroxides with each of leucomethylene blue and dihydroflavins: flavin reductase and the cofactor model exemplified. *ChemMedChem.* 2011; 6(2): 279-291.
- Okada H, Kitaguchi YOH, Yoshimura K. Oxidation reaction of 1, 1'-bis (o-substituted phenyl) ferrocenes. *Org Commun.* 2010; 3(4): 92.
- 12. Dubar F, Egan TJ, Pradines B, et al. The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance. *ACS Chem Biol.* 2011; 6(3): 275-287.
- Pladziewicz JR, Espenson JH. Kinetics and mechanisms of some electron transfer reactions of ferrocenes. J Am Chem Soc. 1973; 95(1): 56-63.
- Pladziewicz JR, Carney MJ. Reduction of ferricenium ion by horse heart ferrocytochrome c. J Am Chem Soc. 1982; 104(12): 3544-3545.
- 15. Pladziewicz JR, Brenner MS, Rodeberg DA, Likar MD. Kinetic study of the oxidation of spinach plastocyanin by ferrocenium ion derivatives. *Inorg Chem.* 1985; 24(10): 1450-1453.
- Carlson BW, Miller LL. Oxidation of NADH by ferrocenium salts. Rate-limiting one-electron transfer. J Am Chem Soc. 1983; 105(25): 7453-7454.
- 17. Matsue T, Suda M, Uchida I, Kato T, Akiba U, Osa T. Electrocatalytic oxidation of NADH by ferrocene derivatives and the influence of cyclodextrin complexation. *J Electroanal Chem Interfac.* 1987; 234(1-2): 163-173.
- Pierre JL, Fontecave M, Crichton RR. Chemistry for an essential biological process: the reduction of ferric iron. *Biometals*. 2002; 15(4): 341-346.
- Woodmansee AN, Imlay JA. Reduced Flavins Promote Oxidative DNA Damage in Non-respiring Escherichia coli by Delivering Electrons to Intracellular Free Iron. J Biol Chem. 2002; 277(37): 34055-34066.
- 20. Takeda K, Iizuka M, Watanabe T, Nakagawa J, Kawasaki S, Niimura Y. Synechocystis DrgA protein functioning as nitroreductase and ferric reductase is capable of catalyzing the Fenton reaction. *The FEBS J.* 2007; 274(5): 1318-1327.
- Delhaes L, Biot C, Berry L, et al. Novel ferrocenic artemisinin derivatives: synthesis, in vitro antimalarial activity and affinity of binding with ferroprotoporphyrin IX. *Bioorg Med Chem.* 2000; 8(12): 2739-2745.
- 22. Paitayatat S, Tarnchompoo B, Thebtaranonth Y, Yuthavong Y. Correlation of antimalarial activity of artemisinin derivatives with binding affinity with ferroprotoporphyrin IX. *J Med Chem.* 1997; 40(5): 633-638.

- 23. Fomin V, Markin A. Oxidation mechanism of ferrocene with molecular oxygen: kinetic and thermodynamic aspects. *J Therm Anal Calorim.* 2008; 92(3): 985-987.
- 24. Haynes RK, Cheu K, N'Da DD, Coghi P, Monti D. Considerations on the mechanism of action of artemisinin antimalarials: Part 1-The 'carbon radical' and 'heme' hypotheses. *Infect Disord Drug Targets*. 2013; 13(4): 217-277.
- Haynes RK. Strategies in the development and chemical modification of the new artemisinin antimalarial artemisone. *Synform*. 2008; 3; 34-36.
- 26. Lin AJ, Zikry AB, Kyle DE. Antimalarial Activity of New Dihydroartemisinin Derivatives. 7. 4-(p-Substituted phenyl)-4 (R or S)-[10 (α or β)-dihydroartemisininoxy] butyric Acids1-6. *J Med Chem.* 1997; 40(9): 1396-1400.
- 27. Vogel M, Rausch M, Rosenberg H. Derivatives of Ferrocene. III. The preparation of some acylferrocenes and alkylferrocenes. *J Org Chem.* 1957; 22(9): 1016-1018.
- 28. Lau CK, Tardif S, Dufresne C, Scheigetz J. Reductive deoxygenation of aryl aldehydes and ketones by tert-butylamine-borane and aluminum chloride. *J Org Chem.* 1989; 54(2): 491-494.
- 29. Verlinden BK, Niemand J, Snyman J, et al. Discovery of novel alkylated (bis) urea and (bis) thiourea polyamine analogues with potent antimalarial activities. *J Med Chem.* 2011; 54(19): 6624-6633.
- Wentzel JF, Lombard MJ, Du Plessis LH, Zandberg L. Evaluation of the cytotoxic properties, gene expression profiles and secondary signalling responses of cultured cells exposed to fumonisin B1, deoxynivalenol and zearalenone mycotoxins. *Arch Toxicol.* 2017; 91(5): 2265-2282.
- 31. Batterjee SM, Marzouk MI, Aazab ME, El-Hashash MA. The electrochemistry of some ferrocene derivatives: redox potential and substituent effects. *Appl Organomet Chem.* 2003; 17(5): 291-297.
- 32. Shago RF, Swarts JC, Kreft E, van Rensgurg CEJ. Antineoplastic activity of a series of ferrocene-containing alcohols. *Anticancer Res.* 2007; 27(5A): 3431-3433.
- 33. Kuwana T, Bublitz DE, Hoh G. Chronopotentiometric studies on the oxidation of ferrocene, ruthenocene, osmocene and some of their derivatives. *J Am Chem Soc.* 1960; 82(22): 5811-5817.
- 34. Little WF, Eisenthal R. Interannular electronic effects in ferrocene: kinetics of reaction of substituted ferrocenoic acids with diphenyldiazomethane. *J Am Chem Soc.* 1961; 83(24): 4936-4939.
- 35. Birrell GW, Chavchich M, Ager AL, et al. JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. *Antimicrob Agents Chemother*. 2015; 59(1): 170-177.
- 36. Lu JJ, Meng LH, Cai YJ, et al. Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen activated protein kinase activation but independent of reactive oxygen species. *Cancer Biol Ther.* 2008; 7(7): 1017-1023.

**Disclaimer**: Any opinions, findings and conclusions, or recommendations expressed in this material are those of the authors and therefore the NRF does not accept any liability in regard thereto. **Supplementary Material** 

Supplementary data associated with this article can be found, in the online version, at